Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference

Journal of Infectious Diseases

Volumn 193, Issue 12, 2006, Pages 1650-1657

  Geisbert, Thomas W ^a   Hensley, Lisa E ^a   Kagan, Elliott ^b   Yu, Erik Zhaoying ^b   Geisbert, Joan B ^a   Daddario DiCaprio, Kathleen ^b   Fritz, Elizabeth A ^a   Jahrling, Peter B ^c   McClintock, Kevin ^d   Phelps, Janet R ^d   Lee, Amy C H ^d   Judge, Adam ^d   Jeffs, Lloyd B ^d   MacLachlan, Ian ^d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Protiva Biotherapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; GENE EXPRESSION; GUINEA PIG; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; STRUCTURAL GENE; VIREMIA; VIRUS HEMORRHAGIC FEVER; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; INTERFERON-ALPHA; INTERFERON-BETA; LIPOSOMES; PLAQUE ASSAY; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA REPLICASE; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; VIREMIA;

EID: 33645720317     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504267     Document Type: Article

References (44)

1. Walsh PD, Abernethy KA, Bermejo M, et al. Catastrophic ape decline in western equatorial Africa. Nature 2003; 422:611-4.
2. International Society for Infectious Diseases. Ebola, lab accident death-Russia (Siberia). Archive no. 20040522.1377. 22 May 2004. Available at: http://www.promedmail.org. Accessed 1 May 2006.
3. Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 1993; 29:215-40.
4. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res 2004; 14:460-6.
5. Colbere-Garapin F, Blondel B, Saulnier A, Pelletier I, Labadie K. Silencing viruses by RNA interference. Microbes Infect 2005; 7:767-75.
6. Fowler T, Bamberg S, Moller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005; 86:1181-8.
7. Sanchez AB, Perez M, Cornu T, de la Torre JC. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 2005; 79:11071-81.
8. Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL. Inhibition of SARS-CoV replication by siRNA. Antiviral Res 2005; 65:45-8.
9. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418:38-9.
10. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8:769-76.
11. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347-51.
12. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101:8676-81.
13. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23:1002-7.
14. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999;179(Suppl 1):S203-17.
15. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
16. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005; 22:362-72.
17. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005; 107:276-87.
18. Stein Y, Halperin G, Stein O. Biological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett 1980; 111:104-6.
19. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-a2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1):S224-34.
20. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol 1986; 6:2279-83.
21. Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 2005; 79:5353-62.
22. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 1979; 43:247-52.
23. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
24. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179(Suppl 1):S199-202.
25. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7.
26. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125:243-53.
27. Bowen ET, Platt GS, Lloyd G, Raymond RT, Simpson DI. A comparative study of strains of Ebola virus isolated from southern Sudan and northern Zaire in 1976. J Med Virol 1980; 6:129-38.
28. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and non-human primates. Virology 1998; 251:28-37.
29. Ryabchikova E, Strelets L, Kolesnikova L, Pyankov O, Sergeev A. Respiratory Marburg virus infection in guinea pigs. Arch Virol 1996; 141:2177-90.
30. Fenske DB, MacLachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol 2002; 346:36-71.
31. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
32. Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther 2000; 7:548-55.
33. Collard WT, Yang Y, Kwok KY, Park Y, Rice KG. Biodistribution, metabolism, and in vivo gene expression of low molecular weight glycopeptide polyethylene glycol peptide DNA co-condensates. J Pharm Sci 2000; 89:499-512.
34. Biessen EA, Vietsch H, Rump ET, et al. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem J 1999; 340 (Pt 3):783-92.
35. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-8.
36. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-62.
37. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70.
38. Isaacson M, Sureau P, Courteille G, Pattyn SR. Clinical aspects of Ebola virus disease at the Ngaliema Hospital, Kinshasa, Zaire. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. New York: Elsevier/North-Holland Biomedical Press, 1978:15-20.
39. Huggins I, Zhang ZX, Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999; 179(Suppl 1):S240-7.
40. Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002; 55:151-9.
41. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408-12.
42. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor Vila/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8.
43. Huggins JW Zhang ZX, Davis K, Coulombe RA. Inhibition of Ebola virus by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Res 1995;26:A301.
44. Parren PW, Geisbert TW, Geisbert I, Sullivan NJ, Jahrling PB, Burton DR. Antibody activity against Ebola virus in vitro and in vivo. In: Program and abstracts of the VRC Symposium on Viral Hemorrhagic Fevers (Bethesda, MD). Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2003.